Spots Global Cancer Trial Database for Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Official Title: A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
Study ID: NCT05900206
Conditions
Study Description
Brief Summary: The goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer. The main questions it aims to answer are: * is T-DXd more effective than standard preoperative treatment? * are there markers in the tumor or blood of patients with HER2-positive breast cancer that can help us predict response to treatment? Participants will be divided into two groups, where one group will be treated with three courses of T-DXd and the other group will be treated with three courses standard of care treatment. Thereafter, further treatment will be decided by the tumor's molecular subtype.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Skåne University Hospital, Malmö, , Sweden
Sankt Gorans Hospital, Stockholm, , Sweden
Stockholm Southern Hospital, Stockholm, , Sweden
Karolinska University Hospital, Stockholm, , Sweden
Norrlands University Hospital, Umeå, , Sweden
Uppsala University Hospital, Uppsala, , Sweden
Örebro University Hospital, Örebro, , Sweden
Contact Details
Name: Theodoros Foukakis, MD/PhD
Affiliation: Karolinska University Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Alexios Matikas, MD/PhD
Affiliation: Karolinska University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
